226 related articles for article (PubMed ID: 18484981)
1. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.
Linder SL; Mathew NT; Cady RK; Finlayson G; Ishkanian G; Lewis DW
Headache; 2008 Oct; 48(9):1326-36. PubMed ID: 18484981
[TBL] [Abstract][Full Text] [Related]
2. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
3. Almotriptan reduces the incidence of migraine-associated symptoms: a pooled analysis.
Cady R
Headache; 2002 Jan; 42 Suppl 1():26-31. PubMed ID: 11966861
[TBL] [Abstract][Full Text] [Related]
4. Spotlight on almotriptan in migraine.
Keam SJ; Goa KL; Figgitt DP
CNS Drugs; 2002; 16(7):501-7. PubMed ID: 12056924
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study.
Cabarrocas X;
Clin Ther; 2001 Nov; 23(11):1867-75. PubMed ID: 11768838
[TBL] [Abstract][Full Text] [Related]
6. Almotriptan: a review of its use in migraine.
Keam SJ; Goa KL; Figgitt DP
Drugs; 2002; 62(2):387-414. PubMed ID: 11817980
[TBL] [Abstract][Full Text] [Related]
7. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
9. Crossover, double-blind clinical trial comparing almotriptan and ergotamine plus caffeine for acute migraine therapy.
Láinez MJ; Galván J; Heras J; Vila C
Eur J Neurol; 2007 Mar; 14(3):269-75. PubMed ID: 17355546
[TBL] [Abstract][Full Text] [Related]
10. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine.
Mathew NT;
Headache; 2002 Jan; 42(1):32-40. PubMed ID: 12005273
[TBL] [Abstract][Full Text] [Related]
11. Almotriptan 12.5 mg in menstrually related migraine: a randomized, double-blind, placebo-controlled study.
Allais G; Bussone G; D'Andrea G; Moschiano F; d'Onofrio F; Valguarnera F; Manzoni GC; Grazzi L; Allais R; Benedetto C; Acuto G
Cephalalgia; 2011 Jan; 31(2):144-51. PubMed ID: 20660540
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
13. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial.
Dowson AJ; Massiou H; Laínez JM; Cabarrocas X
Cephalalgia; 2002 Jul; 22(6):453-61. PubMed ID: 12133045
[TBL] [Abstract][Full Text] [Related]
14. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.
Rapoport AM; Ramadan NM; Adelman JU; Mathew NT; Elkind AH; Kudrow DB; Earl NL
Neurology; 1997 Nov; 49(5):1210-8. PubMed ID: 9371896
[TBL] [Abstract][Full Text] [Related]
15. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Eur Neurol; 2005; 53 Suppl 1():41-8. PubMed ID: 15920337
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine.
Chen LC; Ashcroft DM
Headache; 2007 Sep; 47(8):1169-77. PubMed ID: 17883521
[TBL] [Abstract][Full Text] [Related]
17. DFN-02 (Sumatriptan 10 mg With a Permeation Enhancer) Nasal Spray vs Placebo in the Acute Treatment of Migraine: A Double-Blind, Placebo-Controlled Study.
Lipton RB; Munjal S; Brand-Schieber E; Rapoport AM
Headache; 2018 May; 58(5):676-687. PubMed ID: 29878341
[TBL] [Abstract][Full Text] [Related]
18. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
19. Oral almotriptan in the treatment of migraine: safety and tolerability.
Dodick DW
Headache; 2001 May; 41(5):449-55. PubMed ID: 11380642
[TBL] [Abstract][Full Text] [Related]
20. Frovatriptan: a review of its use in the acute treatment of migraine.
Sanford M
CNS Drugs; 2012 Sep; 26(9):791-811. PubMed ID: 22900951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
